The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year

1998

Stage

Series D | Alive

Total Raised

$64M

Last Raised

$43M | 21 yrs ago

About Signature Bioscience

Signature Bioscience is a Healthcare/Biotechnology company based in Burlingame, California. Signature Bioscience's investors include Abingworth Management, Lotus Biosciences, Vulcan Capital, Tallwood Venture Capital, Coral Group, International Real Returns, Atlas Venture, Lumira Capital, CIBC World Markets, Cowen Capital Partners, China Development Industrial Bank, Prospect Venture Partners and Lehman Brothers.

Signature Bioscience Headquarter Location

1450 Rollins Road

Burlingame, California, 94010,

United States

510-576-2334

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Signature Bioscience Patents

Signature Bioscience has filed 4 patents.

The 3 most popular patent topics include:

  • Analytical chemistry
  • Biotechnology
  • Chromatography
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2017

8/27/2019

Desiccants, Evidence law, Molecular biology, Commodity chemicals, Biotechnology

Grant

Application Date

2/27/2017

Grant Date

8/27/2019

Title

Related Topics

Desiccants, Evidence law, Molecular biology, Commodity chemicals, Biotechnology

Status

Grant

Latest Signature Bioscience News

Circle Pharma Announces Appointment of David Spellmeyer PhD as Chief Scientific Officer

Nov 20, 2017

Dr. Spellmeyer brings over 25 years of broad industrial experience to Circle. He previously served as CTO & CIO at Nodality, CSO at Signature BioScience , Research Staff Member at IBM, as well as scientific, quality systems, and leadership roles at other biotechnology companies. David has been involved in more than 20 strategic corporate partnerships , M&A, and joint ventures, as well as several rounds of venture financing. “We are delighted to welcome David to Circle’s senior leadership,” said David J. Earp, JD, PhD, Circle’s CEO. “His deep experience in rational drug design and discovery is an excellent fit for Circle as we extend our platform for macrocycle discovery and advance our therapeutic pipeline towards the clinic.” “Circle is at an exciting point in its development. I am thrilled to be joining a company that has built such a promising discovery platform,” said Dr. Spellmeyer. “The combination of rational design and efficient, automated macrocycle synthesis is a new approach to this drug class, and the results so far are highly encouraging.” Dr. Spellmeyer received his PhD in 1987 from UCLA, and completed his post-doctoral work in pharmaceutical chemistry at UCSF, where he holds an appointment as an adjunct associate professor in the Department of Pharmaceutical Chemistry. David was named as a Fellow of the American Chemical Society in 2009. He joins Circle’s team after working with the company in his role as an Executive-in-Residence at ShangPharma Innovation, an investor in Circle. He continues to advise ShangPharma in an EIR capacity. About Macrocyclic Peptides Macrocyclic peptides have the potential to allow drug developers to address the large proportion of known therapeutic targets (estimated at up to 80%) that are considered undruggable with conventional small molecule or biologic modalities. In particular, there is great interest in developing macrocycles to modulate protein-protein interactions, which play a role in almost all disease conditions, including cancer, fibrosis, inflammation and infection. However, the development of macrocyclic therapeutics has been limited by the need for a greater understanding of how to develop macrocycles with appropriate pharmacokinetics, cell permeability and oral bioavailability. Circle is applying its ability to design potent macrocycles with intrinsic cell permeability and drug-like characteristics to unlock access to challenging, high value therapeutic targets that have been out of reach to other approaches. About Circle Pharma, Inc. Circle is developing a new paradigm for macrocycle drug discovery based on rational design and synthetic chemistry. Circle’s technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by oral administration. Circle’s macrocycle development platform is applicable across a wide range of serious diseases; the company is initially focusing its internal development efforts on intracellular protein-protein interactions that are key drivers in cancer. Circle’s founders are Prof. Matthew P. Jacobson (Chair of the Dept. of Pharmaceutical Chemistry at UC San Francisco and co-founder of Global Blood Therapeutics (NASDAQ: GBT) and Relay Therapeutics) and Prof. R. Scott Lokey (Dept. of Chemistry and Biochemistry, UC Santa Cruz and director of the UCSC Chemical Screening Center).

  • When was Signature Bioscience founded?

    Signature Bioscience was founded in 1998.

  • Where is Signature Bioscience's headquarters?

    Signature Bioscience's headquarters is located at 1450 Rollins Road, Burlingame.

  • What is Signature Bioscience's latest funding round?

    Signature Bioscience's latest funding round is Series D.

  • How much did Signature Bioscience raise?

    Signature Bioscience raised a total of $64M.

  • Who are the investors of Signature Bioscience?

    Investors of Signature Bioscience include Atlas Venture, CIBC World Markets, Abingworth, Coral Group, Prospect Venture Partners and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.